BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIVDAK (tisotumab vedotin) is an antibody-drug conjugate (ADC) that targets tissue factor (TF) and delivers a microtubule-disrupting payload to cancer cells. It is approved for cervical cancer and represents Pfizer's entry into the ADC oncology space with a novel mechanism. The drug binds tissue factor on tumor vasculature and cancer cells, enabling targeted cytotoxic delivery.
$0.704MPart D
PeakProduct is in peak commercial phase with modest Part D claims (26 in 2023), suggesting specialized oncology market penetration; commercial teams are likely focused on oncology sales and medical education infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Started May 2025
100 enrolled
Cervical Cancer
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Started Jun 2023
19 enrolled
Solid Malignancies
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Started Feb 2021
502 enrolled
Cervical Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Started Mar 2019
98 enrolled
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Started Feb 2019
214 enrolled
Cervical Cancer
Worked on TIVDAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.